Amsterdam Molecular Therapeutics (ATM) B.V. (AMTH.AS)
3.00EUR
24 Dec 2009
€-0.03 (-0.83%)
€3.00
--
€3.03
€3.03
5,190
9,732
€5.28
€2.41
AMTH.AS
About
Overall
| Beta: | 0.17 |
| Market Cap (Mil.): | €44.03 |
| Shares Outstanding (Mil.): | 14.68 |
| Annual Dividend: | -- |
| Yield (%): | -- |
Financials
| AMTH.AS | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 12.83 | 4.73 |
| EPS (TTM): | -26.06 | -- | -- |
| ROI: | -51.84 | 1.39 | 2.81 |
| ROE: | -52.47 | 2.23 | 3.53 |
UPDATE 1-AMT's DMD treatment gains orphan status in Europe
* Orphan status for Duchenne muscular dystrophy treatment
AMT's DMD treatment gains orphan status in Europe
* Orphan status for Duchenne muscular dystrophy treatment
French and Benelux stocks - Factors to watch on Oct 13
PARIS, Oct 13 (Reuters) - Below are company-related news and leading stories from French and Benelux newspapers which could have an impact on the region's markets or individual stocks.
French and Benelux stocks - Factors to watch on June 18
PARIS, June 18 (Reuters) - Below is company-related news and leading stories from French and Benelux newspapers that could have an impact on the region's markets or individual stocks.
STOCKS NEWS EUROPE-AMT shares up on orphan drug designation
Shares in Dutch biotech company AMT gain almost 14 percent to be the second top gainer in a negative Amsterdam market after it says it has been awarded orphan drug designation by the European Medicines Agency for a treatment in development.
Gene therapy edges towards commercial reality
LONDON (Reuters) - Gene therapy may be about to become a commercial reality, 20 years after the first experiments with the ground-breaking medical technology.
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
